Stratos Wealth Partners LTD. Sells 1,761 Shares of Danaher Corporation (NYSE:DHR)

Stratos Wealth Partners LTD. decreased its stake in Danaher Corporation (NYSE:DHR - Free Report) by 22.5% in the first quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 6,081 shares of the conglomerate's stock after selling 1,761 shares during the quarter. Stratos Wealth Partners LTD.'s holdings in Danaher were worth $1,247,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also recently bought and sold shares of DHR. Norges Bank acquired a new stake in Danaher during the 4th quarter worth about $2,130,740,000. GAMMA Investing LLC lifted its holdings in shares of Danaher by 24,958.2% during the 1st quarter. GAMMA Investing LLC now owns 1,870,847 shares of the conglomerate's stock valued at $383,524,000 after buying an additional 1,863,381 shares during the last quarter. Two Sigma Advisers LP lifted its holdings in shares of Danaher by 4,248.8% during the 4th quarter. Two Sigma Advisers LP now owns 1,639,500 shares of the conglomerate's stock valued at $376,347,000 after buying an additional 1,601,800 shares during the last quarter. Capital World Investors lifted its holdings in shares of Danaher by 32.7% during the 4th quarter. Capital World Investors now owns 6,361,183 shares of the conglomerate's stock valued at $1,460,215,000 after buying an additional 1,566,658 shares during the last quarter. Finally, Point72 Asset Management L.P. lifted its holdings in shares of Danaher by 460.6% during the 4th quarter. Point72 Asset Management L.P. now owns 1,348,544 shares of the conglomerate's stock valued at $309,558,000 after buying an additional 1,107,998 shares during the last quarter. 79.05% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on the company. Citigroup reiterated a "buy" rating on shares of Danaher in a report on Monday, April 7th. Wall Street Zen upgraded Danaher from a "hold" rating to a "buy" rating in a report on Friday, June 27th. Deutsche Bank Aktiengesellschaft reduced their price target on Danaher from $240.00 to $235.00 in a report on Thursday, June 5th. UBS Group reduced their price target on Danaher from $275.00 to $240.00 and set a "buy" rating for the company in a report on Wednesday, April 23rd. Finally, Guggenheim reiterated a "buy" rating and set a $250.00 price target on shares of Danaher in a report on Wednesday, April 23rd. Three investment analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $248.43.

Danaher Stock Performance

NYSE DHR traded down $0.71 during trading on Friday, hitting $204.80. The company's stock had a trading volume of 2,369,010 shares, compared to its average volume of 3,504,283. The company has a quick ratio of 1.05, a current ratio of 1.43 and a debt-to-equity ratio of 0.31. The firm has a 50 day moving average price of $196.05 and a 200 day moving average price of $206.47. The firm has a market cap of $146.57 billion, a P/E ratio of 39.77, a price-to-earnings-growth ratio of 2.89 and a beta of 0.77. Danaher Corporation has a 52 week low of $171.00 and a 52 week high of $281.70.

Danaher (NYSE:DHR - Get Free Report) last issued its quarterly earnings results on Tuesday, April 22nd. The conglomerate reported $1.88 EPS for the quarter, topping the consensus estimate of $1.62 by $0.26. The company had revenue of $5.74 billion for the quarter, compared to the consensus estimate of $5.58 billion. Danaher had a return on equity of 10.80% and a net margin of 15.81%. Equities research analysts forecast that Danaher Corporation will post 7.63 earnings per share for the current fiscal year.

Danaher Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, July 25th. Shareholders of record on Friday, June 27th will be given a $0.32 dividend. This represents a $1.28 annualized dividend and a yield of 0.63%. Danaher's dividend payout ratio is currently 24.85%.

Insider Activity at Danaher

In other news, EVP Christopher Paul Riley sold 15,805 shares of the business's stock in a transaction that occurred on Wednesday, April 30th. The stock was sold at an average price of $198.00, for a total transaction of $3,129,390.00. Following the sale, the executive vice president directly owned 15,179 shares in the company, valued at approximately $3,005,442. The trade was a 51.01% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Chairman Steven M. Rales sold 1,250,000 shares of the business's stock in a transaction that occurred on Monday, May 12th. The shares were sold at an average price of $196.74, for a total value of $245,925,000.00. Following the sale, the chairman owned 3,105,808 shares in the company, valued at approximately $611,036,665.92. This represents a 28.70% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 11.10% of the company's stock.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.